Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Subanesthetic esketamine for pain and mood after laparoscopic bariatric surgery
ChiCTR2100050874Phase 4Recruiting
- Sponsor
- Changzhou Second People's Hospital
- Start
- Sep 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of esketamine in postoperative pain, major depressive disorder (MDD) and affective disorder (2 arms), sponsored by Changzhou Second People's Hospital. Primary endpoints: PHQ-9 depression score, Visual analogue scale (VAS) pain score and 3 more. Started Sep 2021; status: recruiting.
02
Drugs
esketamine
03
Conditions
postoperative painmajor depressive disorder (MDD)affective disorder
Beyond the preview
Go deeper on ChiCTR2100050874.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100050874.